Analytics company Clarivate has released its 2026 Drugs to Watch report, with eleven therapies expected to deliver clinical and commercial impact this coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve… Read More
Eleven drugs are projected to achieve blockbuster status or revolutionise treatment paradigms within five years, according to Clarivate’s 2025 Drugs to Watch report. The drugs address critical challenges in areas such as obesity, oncology, and gene therapy, and are forecast to achieve blockbuster sales by 2030 or… Read More
Roche and Johnson & Johnson are the only pharma companies to feature in Clarivate’s 2024 list of Top 100 Global Innovators, which highlights organisations leading the world in technology research and innovation. This is the first year that Clarivate is ranking, rather than just listing, the… Read More
Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among… Read More
Seven companies have been highlighted in Clarivate’s ‘Companies to Watch Report’ for delivering more effective and safer medicines to market faster by leveraging artificial intelligence (AI) and machine learning (ML) technology. From identifying novel targets to simulating how drugs will function in the human body, Clarivate… Read More
The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of… Read More
Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The… Read More
The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. As global macro-economic headwinds, suppressed public markets and political uncertainty weighed on investor confidence,… Read More
Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors. However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from… Read More
Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. Therapies that act upon or incorporate RNA to fight disease have… Read More
A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented. Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1… Read More
